Association of plasma adiponectin concentrations with chronic lymphocytic leukemia and myeloproliferative diseases

Adiponectin, an adipocyte-secreted hormone, is an important negative regulator in the immune system and hematopoiesis. In this study, we investigated the association of adiponectin levels with chronic lymphocytic leukemia (CLL) and myeloproliferative diseases (MPDs). We measured adiponectin levels in 19 patients with CLL and 30 patients with MPD (chronic myclogenous leukemia, 15; polycythemia vera, 9; myelofibrosis, 4; essential thrombocythemia, 2). The data were compared with results from a control group of healthy volunteers who were matched according to age, sex, and body mass index. The adiponectin levels in patients with CLL were lower than in the controls (4.71 +/- 1.33 mu g/mL versus 16.61 +/- 3.91 mu g/mL; P < .001). They were also significantly lower in patients with MPD than in the controls (8.95 +/- 2.64 mu g/mL versus 17.16 +/- 4.77 mu g/mL; P < .001). In addition, we compared the adiponectin levels of MPD patients who were treated with interferon (IFN) to the levels of patients who were not treated with IFN. Adiponectin levels were significantly higher in IFN-treated patients (11.03 +/- 1.39 mu g/mL versus 6.87 +/- 1.79 mu g/mL; P < .001). These results suggest that lymphopoiesis and myelopoiesis negatively influence adiponectin levels. Adiponectin may be related to inflammatory cytokine release. IFN therapy appears to have a positive influence on adiponectin secretion by suppressing inflammatory cytokines. Future studies are needed to prove causality and to provide insight about this hormone's mechanism of action and its potential role regarding the etiology and progression of CLL and MPD.